GSTT1, an increased risk factor for prostate cancer in patients with metabolic syndrome

• Published in: Journal of clinical laboratory analysis Vol. 36; no. 4; pp. e24352 - n/a
• Main Authors: Liu, Dongdong, Che, Bangwei, Chen, Pan, He, Jun, Mu, Yi, Chen, Kehang, Zhang, Wenjun, Xu, Shenghan, Tang, Kaifa
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01-04-2022; John Wiley and Sons Inc
• Subjects: Anticoagulants; Binding sites; Blood pressure; Case-Control Studies; Cholesterol; DNA methylation; Enzymes; Gene polymorphism; genetic polymorphism; Genetic Predisposition to Disease - genetics; Genotype; Genotype & phenotype; Glutathione; Glutathione S-Transferase pi - genetics; Glutathione transferase; Glutathione Transferase - genetics; glutathione transferase gene; GSTM1 protein; GSTT1 protein; High density lipoprotein; Hospitals; Humans; Lipoproteins; Low density lipoprotein; Male; Malignancy; Metabolic syndrome; Metabolic Syndrome - complications; Metabolic Syndrome - epidemiology; Metabolic Syndrome - genetics; Mutation; Older people; Oxidative stress; Polymerase chain reaction; Polymorphism; Prostate cancer; Prostatic Neoplasms - epidemiology; Prostatic Neoplasms - genetics; Regression analysis; Restriction fragment length polymorphism; Risk Factors; metabolic syndrome; glutathione transferase gene; prostate cancer; genetic polymorphism
• ISSN: 0887-8013; 1098-2825
• DOI: 10.1002/jcla.24352

Background
Glutathione S‐transferase (GSTs) gene polymorphism and metabolic syndrome (Mets) are generally considered to be risk factors for prostate cancer (PCa). However, this conclusion is still controversial. There is a close relationship between GSTs gene polymorphism and Mets. We suspect that the effect of GSTs gene polymorphism and Mets on PCa may be the result of their joint action. As a result, the purpose of this study was to investigate the potential effect of GSTs gene polymorphism on PCa in patients with Mets.
Methods
We collected blood samples from 128 patients with PCa and 200 controls. The GSTs gene polymorphism was detected by polymerase chain reaction‐restriction fragment length polymorphism (PCR–RFLP). Age, characteristics of Mets, frequencies of GSTs gene polymorphism, total prostate volume (TPV), Gleason score, and prostate‐specific antigen (PSA) were recorded and analyzed.
Results
There were significant differences in BMI, TG, LDL‐C, FBG, SBP, DBP, and HDL‐C among the control group, N‐PCa group, and Mets‐PCa group (p < 0.05). GSTT1 null genotype (OR = 2.844, 95% CI: 1.791–4.517), GSTM1 null genotype (OR = 2.192, 95% CI: 1.395–3.446), and GSTP1 (A/G + G/G) genotype (OR = 2.315, 95% CI: 1.465–3.657) were associated with PCa susceptibility and malignancy. Only the GSTT1 null genotype in Mets patients was positively correlated with PCa.
Conclusions
Our study suggests that GSTs gene polymorphism may be a risk factor for PCa and can predict the susceptibility and malignancy of PCa. Secondly, in Mets patients, GSTT1 null genotype significantly increased the risk of PCa. GSTM1 null genotype and the effect of GSTP1 (AG + GG) on PCa were not significantly related to Mets.
After Mets was considered, GSTT1 null genotype was only significantly associated with PCa in Mets, and the risk of PCa occurrence increased by 7.867 times (95%CI: 3.073–20.141, p < 0.05), indicating that GSTT1 null genotype may be a significant predictor of PCa occurrence in Mets patients.